References
- Jung J, Jang K, Ju JM et al (2018) Novel cancer gene variants and gene fusions of triple-negative breast cancers (TNBCs) reveal their molecular diversity conserved in the patient-derived xenograft (PDX) model. Cancer Lett 428, 127-138 https://doi.org/10.1016/j.canlet.2018.04.020
- Park J, Jang JH, Park GS, Chung Y, You HJ and Kim JH (2018) BLT2, a leukotriene B4 receptor 2, as a novel prognostic biomarker of triple-negative breast cancer. BMB Rep 51, 373-377 https://doi.org/10.5483/BMBRep.2018.51.8.127
- Dasari S and Tchounwou PB (2014) Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol 740, 364-378 https://doi.org/10.1016/j.ejphar.2014.07.025
- Verma N, Muller AK, Kothari C et al (2017) Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4-NDRG1 Axis. Cancer Res 77, 86-99 https://doi.org/10.1158/0008-5472.CAN-16-1797
- Qin H, Liu X, Li F et al (2017) PAD1 promotes epithelial-mesenchymal transition and metastasis in triple-negative breast cancer cells by regulating MEK1-ERK1/2-MMP2 signaling. Cancer Lett 409, 30-41 https://doi.org/10.1016/j.canlet.2017.08.019
- Kim HB and Myung SJ (2018) Clinical implications of the Hippo-YAP pathway in multiple cancer contexts. BMB Rep 51, 119-125 https://doi.org/10.5483/BMBRep.2018.51.3.018
- Ludwik KA, Campbell JP, Li M et al (2016) Development of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast Cancer. Mol Cancer Ther 15, 2598-2608 https://doi.org/10.1158/1535-7163.MCT-16-0106
- Lin L, White SA and Hu K (2019) Role of p90RSK in Kidney and Other Diseases. Int J Mol Sci 20, pii: E972
- Chen S and Mackintosh C (2009) Differential regulation of NHE1 phosphorylation and glucose uptake by inhibitors of the ERK pathway and p90RSK in 3T3-L1 adipocytes. Cell Signal 21, 1984-1993 https://doi.org/10.1016/j.cellsig.2009.09.009
- Ikuta M, Kornienko M, Byrne N et al (2007) Crystal structures of the N-terminal kinase domain of human RSK1 bound to three different ligands: Implications for the design of RSK1 specific inhibitors. Protein Sci 16, 2626-2635 https://doi.org/10.1110/ps.073123707
- Tas I, Han J, Park SY et al (2019) Physciosporin suppresses the proliferation, motility and tumourigenesis of colorectal cancer cells. Phytomedicine 56, 10-20 https://doi.org/10.1016/j.phymed.2018.09.219
- Melhuish TA, Kowalczyk I, Manukyan A et al (2018) Myt1 and Myt1l transcription factors limit proliferation in GBM cells by repressing YAP1 expression. Biochim Biophys Acta Gene Regul Mech 1861, 983-995 https://doi.org/10.1016/j.bbagrm.2018.10.005
- de Cassia Viu Carrara R, Fontes AM, Abraham KJ et al (2018) Expression differences of genes in the PI3K/AKT, WNT/b-catenin, SHH, NOTCH and MAPK signaling pathways in CD34+ hematopoietic cells obtained from chronic phase patients with chronic myeloid leukemia and from healthy controls. Clin Transl Oncol 20, 542-549 https://doi.org/10.1007/s12094-017-1751-x
- Lim W, Yang C, Park S, Bazer FW and Song G (2017) Inhibitory Effects of Quercetin on Progression of Human Choriocarcinoma Cells Are Mediated Through PI3K/AKT and MAPK Signal Transduction Cascades. J Cell Physiol 232, 1428-1440 https://doi.org/10.1002/jcp.25637
- Zhao T, Li R, Tan X et al (2018) Simulated Microgravity Reduces Focal Adhesions and Alters Cytoskeleton and Nuclear Positioning Leading to Enhanced Apoptosis via Suppressing FAK/RhoA-Mediated mTORC1/NF-kappaB and ERK1/2 Pathways. Int J Mol Sci 19, 1994 https://doi.org/10.3390/ijms19071994
- Sheng W, Chen C, Dong M et al (2017) Calreticulin promotes EGF-induced EMT in pancreatic cancer cells via Integrin/EGFR-ERK/MAPK signaling pathway. Cell Death Dis 8, e3147 https://doi.org/10.1038/cddis.2017.547
- Kuwano M, Shibata T, Watari K and Ono M (2019) Oncogenic Y-box binding protein-1 as an effective therapeutic target in drug-resistant cancer. Cancer Sci 110, 1536-1543 https://doi.org/10.1111/cas.14006
- Moon HG, Yi JK, Kim HS et al (2012) Phosphorylation of p90RSK is associated with increased response to neoadjuvant chemotherapy in ER-positive breast cancer. BMC Cancer 12, 585 https://doi.org/10.1186/1471-2407-12-585
- Ashaie MA and Chowdhury EH (2016) Cadherins: The Superfamily Critically Involved in Breast Cancer. Curr Pharm Des 22, 616-638 https://doi.org/10.2174/138161282205160127095338
- Wang Y and Zhou BP (2011) Epithelial-mesenchymal transition in breast cancer progression and metastasis. Chin J Cancer 30, 603-611 https://doi.org/10.5732/cjc.011.10226
- Hong J, Zhou J, Fu J et al (2011) Phosphorylation of serine 68 of Twist1 by MAPKs stabilizes Twist1 protein and promotes breast cancer cell invasiveness. Cancer Res 71, 3980-3990 https://doi.org/10.1158/0008-5472.CAN-10-2914
- Lin S, Zhang C, Liu F et al (2019) Actinomycin V Inhibits Migration and Invasion via Suppressing Snail/Slug-Mediated Epithelial-Mesenchymal Transition Progression in Human Breast Cancer MDA-MB-231 Cells In Vitro. Mar Drugs 17, 305 https://doi.org/10.3390/md17050305
- Harquail J, LeBlanc N, Landry C, Crapoulet N and Robichaud GA (2018) Pax-5 Inhibits NF-kappaB Activity in Breast Cancer Cells Through IKKepsilon and miRNA-155 Effectors. J Mammary Gland Biol Neoplasia 23, 177-187 https://doi.org/10.1007/s10911-018-9404-4
- Heo KS, Chang E, Takei Y et al (2013) Phosphorylation of protein inhibitor of activated STAT1 (PIAS1) by MAPK-activated protein kinase-2 inhibits endothelial inflammation via increasing both PIAS1 transrepression and SUMO E3 ligase activity. Arterioscler Thromb Vasc Biol 33, 321-329 https://doi.org/10.1161/ATVBAHA.112.300619
- Heo KS, Le NT, Cushman HJ et al (2015) Disturbed flow-activated p90RSK kinase accelerates atherosclerosis by inhibiting SENP2 function. J Clin Invest 125, 1299-1310 https://doi.org/10.1172/JCI76453